Meeting
2023 ASCO Annual Meeting
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
Authors
Arndt Vogel
Hannover Medical School, Hannover, Germany
Arndt Vogel , Tim Meyer , Eric Assenat , Mariona Calvo Campos , Songzi Li , Yaxi Chen , Frederic Boisserie , Ramil Abdrashitov , Donatella Marino , Richard S. Finn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03412773
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4082)
DOI
10.1200/JCO.2023.41.16_suppl.4082
Abstract #
4082
Poster Bd #
403
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).
First Author: Masatoshi Kudo
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus toripalimab as first-line treatment for patients with unresectable hepatocellular carcinoma: Updated results of the ALTER-H003 trial.
First Author: Haifeng Lin
Poster
2019 ASCO Annual Meeting
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jian-Ming Xu
Poster
2018 ASCO Annual Meeting
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
First Author: Shukui Qin